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Abstract
Background: The purpose of this investigation was to determine the effects of a dietary supplement (Ambrotose
AO®) on resting and exercise-induced blood antioxidant capacity and oxidative stress in exercise-trained and
untrained men and women.
Methods: 25 individuals (7 trained and 5 untrained men; 7 trained and 6 untrained women) received Ambrotose
AO® (4 capsules per day = 2 grams per day) or a placebo for 3 weeks in a random order, double blind cross-over
design (with a 3 week washout period). Blood samples were collected at rest, and at 0 and 30 minutes following a
graded exercise treadmill test (GXT) performed to exhaustion, both before and after each 3 week supplementation
period. Samples were analyzed for Trolox Equivalent Antioxidant Capacity (TEAC), Oxygen Radical Absorbance
Capacity (ORAC), malondialdehyde (MDA), hydrogen peroxide (H2O2), and nitrate/nitrite (NOx). Quality of life was
assessed using the SF-12 form and exercise time to exhaustion was recorded. Resting blood samples were
analyzed for complete blood count (CBC), metabolic panel, and lipid panel before and after each 3 week
supplementation period. Dietary intake during the week before each exercise test was recorded.
Results: No condition effects were noted for SF-12 data, for GXT time to exhaustion, or for any variable within the
CBC, metabolic panel, or lipid panel (p > 0.05). Treatment with Ambrotose AO® resulted in an increase in resting
levels of TEAC (p = 0.02) and ORAC (p < 0.0001). No significant change was noted in resting levels of MDA, H2O2,
or NOx (p > 0.05). Exercise resulted in an acute increase in TEAC, MDA, and H2O2 (p < 0.05), all which were higher
at 0 minutes post exercise compared to pre exercise (p < 0.05). No condition effects were noted for exercise
related data (p > 0.05), with the exception of ORAC (p = 0.0005) which was greater at 30 minutes post exercise for
Ambrotose AO® compared to placebo.
Conclusion: Ambrotose AO® at a daily dosage of 4 capsules per day increases resting blood antioxidant capacity
and may enhance post exercise antioxidant capacity. However, no statistically detected difference is observed in
resting or exercise-induced oxidative stress biomarkers, in quality of life, or in GXT time to exhaustion.
Background
Oxidative stress may occur when the production of reac-
tive oxygen and nitrogen species (RONS) overwhelms
endogenous and exogenous antioxidant defenses, with
the potential outcome being oxidation of large and small
molecules within a variety of susceptible tissues [1]. Such
findings have been reported in hundreds of investigations
over the past several years, both in a rested state [2], as
well as in response to aerobic [3] and anaerobic [4] exer-
cise. While it is well accepted that a low level of RONS
production is absolutely necessary to maintain normal
physiological function [5], as well as to allow for exer-
cise-induced adaptations to the endogenous antioxidant
defense system [6,7], excessive RONS production may
lead to the oxidation of lipids, proteins, and nucleic acids,
which may ultimately impair normal cellular function [8].
For example, significant and acute elevations in RONS
may impair muscle force production [9], in addition to
impede exercise recovery [10]. Moreover, a chronic eleva-
tion in RONS and oxidative stress is implicated in the
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involved in the aging process [8]. Therefore, it has been
the objective of many investigators and clinicians to
minimize oxidative stress levels, often done with the use
of supplemental antioxidant nutrient intake.
Although antioxidant intake through whole foods, as
well as low to moderate dose nutritional supplements, is
generally considered to provide health-enhancing bene-
fits, higher-dose supplemental antioxidant intake is
somewhat controversial [12,13]. This controversy is
related to isolated findings that antioxidant use (1000 mg
vitamin C alone [12] or in combination with 400 IU vita-
min E [13]) has been reported to attenuate certain adap-
tations that are commonly observed as a result of chronic
exercise training, including enhanced parameters of insu-
lin sensitivity [13], as well as an up-regulation in endo-
genous antioxidant enzymes, mitochondrial biogenesis,
and endurance capacity [12]. Such findings suggest the
possible need for nutritional supplements which provide
a well-balanced array of antioxidant nutrients, at rela-
tively low dosages, which may function together to pro-
vide increased antioxidant defense.
Indeed, supplemental antioxidant use is a popular prac-
tice, with an estimated 30% of Americans consuming
some sort of antioxidant supplement in 2004 [14]. Based
on current trends in the dietary supplement industry, it is
likely that this number is actually higher today. While
many popular antioxidants have been studied primarily
within animal models or in vitro systems, and used at
dosages that far exceed present recommended intake
values, it is unknown what the optimal antioxidant(s) is
for human supplementation.
In an effort to provide a scientifically sound and con-
sumer friendly antioxidant supplement, many companies
now include antioxidant “blends” consisting of a variety
of antioxidants designed to work in conjunction with
one another in redox cycling. One such product is
Ambrotose AO® (Mannatech, Incorporated, Coppell,
TX). The Ambrotose AO® supplement is a multi-
component, food based, dietary supplement containing a
proprietary blend of both lipid and water soluble antiox-
idants. In a recently published study involving a mixed
sample of male and female smokers and non smokers
[15], Ambrotose AO® increased serum Oxygen Radical
Absorbance Capacity (ORAC) by 36.6% when subjects
ingested up to 8 capsules daily (500 mg per capsule =
4000 mg per 8 capsules). This study involved an open-
label design, using an escalating dosing schedule of 1, 2,
4, and 8 capsules daily, over the course of a 5 week per-
iod. Using a quadratic function in an attempt to esti-
mate the optimal dosage of Ambrotose AO® to increase
serum ORAC, the authors concluded that a daily dosage
of 4.7 capsules per day may be ideal. Similar findings for
the increase in serum ORAC were noted in another
open-label study performed by Boyd and colleagues
[16], when male and female smokers and non smoking
subjects ingested only 1000 mg per day of Ambrotose
AO® for two weeks. While these data are interesting,
shortcomings of these studies include the use of an
open label design, the failure to include multiple bio-
markers of oxidative stress, and the analysis of blood
samples collected from subjects while only in a rested
state.
Based on these findings, we believed that a logical fol-
low-up to this research would be to investigate the
effects of Ambrotose AO® on a variety of oxidative stress
biomarkers, not only at rest (as done in the previous
studies), but also in response to an acute exercise stres-
sor. Within the field of sport nutrition, the use of anti-
oxidants (typically at high dosages) as protective agents
against the stressful effects of acute exercise has received
considerable attention in recent years [17,18]. Determin-
ing the effects of the Ambrotose AO® supplement under
such a condition is thus very timely.
Hence, the purpose of the present study was to investi-
gate the effects of Ambrotose AO® on resting and exer-
cise-induced antioxidant capacity and oxidative stress
biomarkers. In an attempt to determine if differences in
responses occurred between exercise trained and
untrained subjects, our sample consisted of both trained
and untrained men and women. We hypothesized that
Ambrotose AO® supplementation would result in an
increase in resting antioxidant capacity and a decrease in
oxidative stress biomarkers. Additionally, it was hypothe-
sized that acute exercise would result in an increase in
oxidative stress in both conditions, with attenuation
observed with the Ambrotose AO® condition.
Methods
Subjects and Screening
Young to middle aged (20-49 yrs) exercise trained (n = 7)
a n du n t r a i n e d( n=7 )m e na n de x e r c i s et r a i n e d( n=7 )
and untrained (n = 7) women were initially recruited to
participate. Eligibility was determined by completion of
health history, drug and dietary supplement usage, and
physical activity questionnaires. Subjects were considered
to be “exercise trained” if they were engaged in regular
exercise for a minimum of 4 hours per week prior to
being enrolled in the study, while untrained subjects did
not exercise regularly. All subjects were instructed to
maintain their pre-study training program throughout
the course of the study. In determining the weekly hours
of exercise, the total time of the exercise session was
accounted for and not simply the time engaged in the
activity. For example, resistance training involves both
work and rest intervals. In this case the cumulative time
was considered and not simply the time of “work”. Activ-
ities including walking, jogging, cycling, stepping,
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classified as “aerobic” exercise. Activities including
machine and free weight resistance training and sprinting
were classified as “anaerobic” exercise. While we under-
stand that machine and free weight resistance exercise, as
well as high intensity sprint exercise, may result in adap-
tations to the cardiorespiratory system as well as the
metabolic and skeletal muscle systems, for our classifica-
tion purposes, such exercise was indicated as anaerobic.
No attempt was made to classify exercise type based on
percentage of heart rate response, blood lactate, etc. See
Table 1 for subject descriptive characteristics. Subjects
were nonsmokers, did not report any history of cardio-
vascular or metabolic disorders, and did not use nutri-
tional supplements (or were willing to stop their use
before and throughout the study period). Prior to partici-
pation, each subject was informed of all procedures,
potential risks, and benefits associated with the study
through both verbal and written form in accordance with
the approved procedures of the University Institutional
Review Board for Human Subjects Research. Subjects
signed an informed consent form prior to being admitted
as a subject.
Measurements
Subjects’ height (via stadiometer), weight (via electronic
scale), and body composition (via a 7 site skinfold test
and calculation using the Siri equation) was measured.
Heart rate (via 60 second palpation) and blood pressure
(via auscultation) were recorded following a 10 minute
period of quiet rest. A maximal graded exercise test
(GXT) was conducted using a treadmill, and subjects
continued until exhaustion.
Graded Exercise Test
Following each 21 day period of Ambrotose AO® and pla-
cebo intake, subjects reported to the lab in the morning
to perform a GXT on a treadmill. A GXT was chosen for
the exercise stressor, as this test involves both an aerobic
and anaerobic component. Both forms of exercise have
been reported to result in an acute increase in oxidative
stress [3,4], possibly due to a combination of factors such
as increased oxygen consumption, catecholamine auto-
oxidation, ischemia-reperfusion, prostanoid metabolism,
xanthine oxidase activity, inflammation, and malfunc-
tions in calcium handling [4]. In an attempt to maintain
consistency in testing, a script was read to each subject
prior to performing the GXT. The protocol involved an
increase in intensity every 2 minutes in the following
manner: min 1-2, 3.0 mph, 0%; min 3-4, 3.5 mph, 0%;
min 5-6, 4.0 mph, 0%; min 7-8, 4.5 mph, 0%; min 9-10,
5.0 mph, 0%; min 11-12, 5.0 mph, 5%; min 13-14, 5.5
mph, 5%; min 15-16, 5.5 mph, 7.5%; min 17-18, 6.0 mph,
7.5%; min 19-20, 6.0 mph, 10%; min 21-22, 6.5 mph, 10%;
min 23-24, 6.5 mph, 12.5%; min 25-26, 7.0 mph, 12.5%.
Using the above protocol, for most subjects minutes 1-6
served as an aerobic warm-up, minutes 7-12 served as an
initial aerobic/anaerobic challenge, and times after 12
minutes served to anaerobically stress the subject until
they reached exhaustion. No subject exceeded 25 minutes
Table 1 Descriptive characteristics of subjects
Variable Trained Men (n = 7) Untrained Men (n = 5) Trained Women (n = 7) Untrained Women (n = 6)
Age (yrs) 31.1 ± 5.8 32.2 ± 9.9 26.0 ± 9.1 28.8 ± 4.6
Height (cm)* 181.8 ± 9.4 176.8 ± 9.3 165.8 ± 6.7 164.3 ± 1.7
Weight (kg)* 82.1 ± 10.0 85.4 ± 8.5 61.4 ± 11.6 60.4 ± 5.2
BMI (kg·m
-2)* 24.8 ± 2.2 27.3 ± 3.0 22.2 ± 2.7 22.3 ± 2.0
Body fat (%)†* 11.2 ± 5.5 17.5 ± 5.4 18.7 ± 5.6 23.8 ± 5.7
Waist (cm)* 84.8 ± 5.0 89.7 ± 9.4 68.8 ± 4.6 70.6 ± 3.7
Hip (cm)* 102.6 ± 6.0 104.2 ± 4.7 95.9 ± 7.6 96.3 ± 4.9
Waist:Hip* 0.83 ± 0.03 0.86 ± 0.08 0.71 ± 0.04 0.73 ± 0.03
Resting HR (bpm) 57.1 ± 6.7 62.6 ± 8.6 60.0 ± 14.4 71.5 ± 10.1
Resting SBP (mmHg)* 121.1 ± 9.6 125.6 ± 12.1 114.7 ± 4.1 112.3 ± 7.6
Resting DBP (mmHg)* 80.3 ± 8.3 85.6 ± 5.4 72.6 ± 6.4 77.0 ± 3.7
Years Anaerobic Exercise† 10.1 ± 3.7 0.8 ± 1.2 8.4 ± 9.8 0.5 ± 0.8
Hours per week Anaerobic Exercise† 3.3 ± 0.9 0.4 ± 1.2 4.5 ± 2.9 0.3 ± 0.5
Years Aerobic Exercise† 9.1 ± 9.7 2.6 ± 4.4 4.1 ± 3.7 1.6 ± 5.2
Hours per week Aerobic Exercise† 4.0 ± 3.9 0.7 ± 0.6 4.6 ± 3.6 0.6 ± 0.6
Values are mean ± SD.
†Training status effect: Body fat (p = 0.02); Years Anaerobic Exercise (p = 0.001); Hours per week Anaerobic Exercise (p = 0.0001); Years Aerobic Exercise (p =
0.02); Hours per week Aerobic Exercise (p = 0.004).
*Sex effect: Height (p < 0.0001); Weight (p < 0.0001); BMI (p = 0.0009); Body fat (p = 0.007); Waist (p < 0.0001); Hip (p = 0.008); Waist:Hip (p < 0.0001); Resting
SBP (p = 0.01); Resting DBP (p = 0.004).
No other statistically significant differences were noted (p > 0.05).
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lowing each of the 3 week supplementation periods, with
the exact script read prior to each GXT. Before and dur-
ing the GXT, heart rate was continuously monitored via
electrocardiograph (ECG) tracings using a SensorMedics
Max-1™ ECG unit and the Borg scale of exertion was
used to allow subjects to indicate their level of perceived
work. Total exercise time was also recorded. Although
subjects performed the GXT in the morning following
an overnight fast, they were allowed to drink water
ad libitum before and following the GXT.
While we were primarily interested in generating an
increase in RONS production by having subjects perform
the GXT, rather than in monitored hemodynamics, the
blood pressure response to exercise was not measured.
Hence, we are unable to provide data related to the rate
pressure product during exercise. Moreover, we did not
collect expired gases during exercise, as doing so some-
times limits subjects’ effort due to difficulty in breathing
into a facemask with the inability to breathe through the
nose. Therefore, we are unable to provide data related to
VO2 max during exercise. Our failure to include the above
measures may be considered by some to be limitations of
this work.
At the conclusion of the GXT, a full explanation of
dietary data recording was provided to subjects, along
with data collection forms. An overview of all study pro-
cedures was also provided. Subjects were then assigned
their initial condition (Ambrotose AO® or placebo),
instructed on how to take the capsules, and scheduled
for their remaining laboratory visits.
Supplementation
The study design involved a random order, cross-over
assignment to Ambrotose AO® or placebo in a double
blind manner. A schematic overview of the study timeline
is presented in Figure 1. Subjects ingested 4 capsules per
day of Ambrotose AO® or placebo with meals (2 capsules
in the morning and 2 capsules in the evening) for a total
of 21 days, with a 21 day wash out period between condi-
tions. Both the Ambrotose AO® and placebo capsules (cel-
lulose) were provided by Mannatech, Incorporated
(Coppell, TX), and were virtually identical in appearance
and texture. Each capsule of Ambrotose AO® contained 18
mg vitamin E as mixed tocopherols; 113 mg of an antioxi-
dant blend (quercetin dihydrate; grape skin extract; green
tea extract; Terminalia ferdinandiana [Australian bush
plum powder], 331 mg of a proprietary blend of plant
polysaccharides and fruits and vegetables powders (aloe
vera inner leaf gel, gum acacia, xanthan gum, gum traga-
canth, gum ghatti, broccoli, Brussels sprouts, cabbage, car-
rot, cauliflower, garlic, kale, onion, tomato, turnip, papaya
and pineapple). For both conditions, capsules were distrib-
uted to subjects by research assistants in unlabeled bottles
in amounts greater than needed for supplementation.
Capsule counts upon bottle return allowed for estimation
of compliance to intake.
SF-12 Questionnaire
Subjects were asked to complete a questionnaire per-
taining to their overall mental and physical health status
(SF-12v2; QualityMetric, Inc.). The questionnaire was
delivered using a computer based program and scoring
was performed using automated software immediately
following completion of the questionnaire.
Blood Sampling
Venous blood samples (~20 mL) were collected from
subjects’ forearm via needle and Vacutainer™ before and
following each 21 day period of supplementation with
Ambrotose AO® and placebo (blood collections occurred
on days 1 and 22). Measurements of all antioxidant and
oxidative stress variables were done at rest (following a
10 minute quiet rest), immediately after the GXT, and 30
minutes after the GXT. For resting samples only (pre and
post intervention), a portion of blood was processed
accordingly and sent to Laboratory Corporation of Amer-
ica for analysis of complete blood count, metabolic panel,
and lipid panel within 24 hours of collection using auto-
mated clinical analyzers. Samples collected in containers
with no additive were allowed to clot for 30 minutes at
room temperature and were then centrifuged at 2000 g at
4°C to obtain serum. Samples collected in containers with
EDTA were immediately centrifuged at 2000 g at 4°C to
obtain plasma. Following centrifugation, the serum/
plasma was immediately stored in multiple aliquots in an
ultra-low freezer until analyzed for antioxidant and
oxidative stress variables.
Biochemistry: Antioxidant and Oxidative Stress Variables
The following variables representing antioxidant capa-
city and oxidative stress were chosen based on their use
within the exercise science/nutrition literature, in parti-
cular related to oxidative stress markers [19]. A second
consideration was their relative ease of analysis, in that
replication of this work would be possible by most
laboratories. A limitation of this work is the exclusion of
protein and DNA specific markers of oxidative stress
such as protein carbonyls and 8-hydroxydeoxyguanosine,
as well as the exclusion of individual enzymatic and
non-enzymatic antioxidants.
Antioxidant capacity was analyzed in serum using the
Trolox-Equivalent Antioxidant Capacity (TEAC) assay
using procedures outlined by the reagent provider
(Sigma Chemical; St. Louis, MO). Antioxidant capacity
was also analyzed in serum (following a 750 fold dilu-
tion) using the Oxygen Radical Absorbance Capacity
(ORAC) assay using procedures outlined by the reagent
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should be noted that several methods are available to
assess the “total” antioxidant capacity of blood. These
include TEAC (which appears primarily influenced by
urate) and ORAC, as well as the ferric reducing ability
of plasma (FRAP) assay and the total radical-trapping
antioxidant parameter (TRAP) assay. Of these, ORAC
and FRAP have been noted to be well-correlated, while
TEAC is not correlated with ORAC or FRAP, and may
underestimate antioxidant capacity [20]. Therefore, as
with the oxidative stress biomarkers, we chose to
include more than one antioxidant capacity marker, as
has been suggested previously [21].
Malondialdehyde (MDA) was analyzed in plasma
using a commercially available colorimetric assay
(Northwest Life Science Specialties; Vancouver, WA),
using the modified method described by Jentzsch et al.
[22]. Hydrogen peroxide (H2O2) was analyzed in plasma
using the Amplex Red reagent method as described by
the manufacturer (Molecular Probes; Invitrogen Detec-
tion Technologies, Eugene, OR). Nitric oxide (NOx) was
estimated using the nitrate/nitrite assay procedure as
described by the manufacturer (Caymen Chemical; Ann
Arbor, MI). All assays were performed on first thaw.
Dietary Intake and Physical Activity
All subjects were instructed to maintain their normal
diet, without attempts to increase or decrease antioxidant
nutrient intake. Subjects recorded their food and bever-
age intake during the seven days prior to each exercise
test day. Nutritional records were analyzed for total cal-
ories, protein, carbohydrate, fat, and a variety of micro-
nutrients (Food Processor SQL, version 9.9, ESHA
Research, Salem, OR). Subjects were given specific
instructions regarding abstinence from alcohol consump-
tion during the 48 hours immediately preceding the test
days. They were instructed to maintain their normal phy-
sical activity, with the exception of refraining from stren-
uous physical activity during the 48 hours preceding each
test day.
Statistical Analysis
For the main analysis, all outcomes measures were ana-
lyzed using a condition × time × training status × sex
repeated measures analysis of variance (ANOVA). All
resting blood measures (antioxidant capacity, oxidative
stress, complete blood count, metabolic panel, lipid
panel), in addition to SF-12 data, were analyzed using a
condition × time (pre and post intervention) × training
status × sex ANOVA. Exercise time to exhaustion data
were analyzed using a condition × training status × sex
ANOVA. Single degree of freedom contrasts, a form of
post hoc testing which explicitly compares the effect of
the independent variable on the outcome variables, were
performed where appropriate. Dietary and supplement
compliance data were analyzed using a t-test. Effect size
Figure 1 Timeline of study to investigate the effect of Ambrotose AO® on resting and exercise-induced antioxidant capacity and
oxidative stress in healthy adults.
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lyses were performed using JMP statistical software (ver-
sion 4.0.3, SAS Institute, Cary, NC). Statistical
significance was set at p ≤ 0.05. The data are presented
as mean ± SEM, except for subject descriptive charac-
teristics (mean ± SD).
Results
Overview and Compliance
Although 28 subjects were initially enrolled in the study,
two untrained men dropped out during the first 3 weeks
of the study due to lack of interest, and one untrained
woman was dropped during the final 2 weeks of the
study due to an acute illness (minor nosebleeds), which
was determined to be unrelated to the study protocol.
Therefore, only 25 subjects were included in the analysis
(see Table 1 for descriptive characteristics). Regarding
compliance to capsule intake, subjects were 90% compli-
ant to Ambrotose AO® capsules and 93% compliant to
placebo capsules, with no statistical difference noted
between conditions (p > 0.05). Compared with untrained
subjects, however, trained subjects were significantly
more compliant (p < 0.05). Data are presented in Table 2.
SF-12 Data
No condition differences were noted for either mental or
physical SF-12 data (p > 0.05). However, a difference was
noted for physical health between trained and untrained
subjects (p < 0.05). Data are presented in Table 2.
Exercise Test Data
No condition differences were noted for GXT time to
exhaustion (p > 0.05). However, a difference was noted
between men and women and between trained and
untrained subjects (p < 0.05). Data are presented in
Table 2.
Complete Blood Count, Metabolic Panel, Lipid Panel Data
No condition differences were noted for complete blood
count (Table 3), metabolic panel (Table 4), or lipid
panel (Table 5) (p > 0.05). However, several differences
were noted between men and women and between
trained and untrained subjects for these variables (p <
0.05), as can be seen in Tables 3, 4, and 5.
Dietary Data
No difference was noted between conditions in subjects’
dietary intake for total kilocalories, grams of protein,
carbohydrate, or fat, or for vitamin C, vitamin E, or vita-
min A intake (p > 0.05). However, other than vitamin E,
trained subjects consumed significantly more of each
nutrient category than untrained subjects and men con-
sumed significantly more than women (p < 0.05). Data
are presented in Table 6.
Antioxidant Capacity and Oxidative Stress Biomarker
Data: Resting
With regards to the pre-post intervention comparison of
Ambrotose AO® and placebo in resting blood samples,
the findings were as follows: For TEAC, a sex × training
status × condition effect was noted (p = 0.009), with
trained men having the highest TEAC with the Ambro-
tose AO® condition. A sex effect was also noted (p <
0.0001), with men having higher values than women.
A time effect was also noted (p = 0.01), with values
higher post intervention compared to pre intervention.
No other effects were noted for TEAC (p > 0.05).
Although the condition × time interaction effect was not
significant (p = 0.17), contrast analysis indicated that
TEAC was higher post intervention compared to pre
intervention for the Ambrotose AO® condition (p = 0.02;
Cohen’s d = 0.63). Data are presented in Figure 2A.
For ORAC, a sex effect (p = 0.003; women having
higher values than men), a time effect (p = 0.04; post
intervention higher than pre intervention), a training
status effect (p = 0.0002; trained subjects higher than
untrained), and a condition effect (p = 0.008; placebo
higher than Ambrotose AO®) was noted. A sex × train-
ing status effect was noted (p < 0.0001), with trained
women higher than all other groups of participants.
A condition × time effect was also noted (p = 0.01),
with ORAC increasing more from pre to post interven-
tion with Ambrotose AO® than with placebo. Contrast
analysis indicated that ORAC was higher post interven-
tion compared to pre intervention for the Ambrotose
AO® condition (p < 0.0001; Cohen’s d =1 . 6 7 ) .N oo t h e r
effects were noted for ORAC (p > 0.05). Data are pre-
sented in Figure 2B.
For MDA, a sex effect was noted (p < 0.0001), with
men having higher values than women. No other effects
were noted for MDA (p > 0.05). Data are presented in
Figure 3A.
For H2O2, a sex effect was noted (p = 0.03), with men
having higher values than women. No other effects were
noted for H2O2 (p > 0.05). Data are presented in Figure 3B.
For NOx, no significant effects were noted (p > 0.05),
although the condition × time interaction approached
statistical significance (p = 0.11). Contrast analysis indi-
cated a trend for higher NOx post intervention com-
pared to pre intervention for the Ambrotose AO®
condition (p = 0.12; Cohen’s d =0 . 4 9 ) .D a t aa r ep r e -
sented in Figure 3C.
Antioxidant Capacity and Oxidative Stress Biomarker
Data: Exercise-Induced
With regards to the pre-post intervention comparison of
Ambrotose AO® and placebo in blood samples collected
before and after acute exercise, the findings were as fol-
lows: For TEAC, a sex effect was noted (p < 0.0001),
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effect was also noted (p = 0.02), with values higher at 0
minutes post exercise compared to rest (pre exercise).
Data are presented in Figure 4A. No other effects were
noted for TEAC (p > 0.05), although the training status
effect approached statistical significance (p = 0.09), with
trained subjects having higher values than untrained
subjects.
For ORAC, a sex effect (p = 0.01; women having higher
values than men), a training status effect (p < 0.0001;
trained subjects higher than untrained), and a condition
effect (p = 0.0005; Ambrotose AO® higher than placebo)
was noted. A sex × training status effect was noted (p <
0.0001), with trained women higher than all other groups
of participants. A condition × time effect was also noted
(p < 0.0001), with ORAC higher at 30 minutes post exer-
cise for Ambrotose AO® as compared to placebo. No
other effects were noted for ORAC (p > 0.05). Data are
presented in Figure 4B.
For MDA, a sex effect was noted (p < 0.0001), with
men having higher values than women. A time effect was
a l s on o t e d( p=0 . 0 5 ) ,w i t hv a l u e sh i g h e ra t0m i n u t e s
post exercise compared to rest (pre exercise). Data are
presented in Figure 5A. No other effects were noted for
MDA (p > 0.05).
For H2O2, a sex effect was noted (p = 0.007), with
men having higher values than women. A time effect
was also noted (p < 0.0001), with values higher at 0
minutes post exercise compared to rest (pre exercise).
Data are presented in Figure 5B. No other effects were
noted for H2O2 (p > 0.05).
For NOx, no significant effects were noted (p > 0.05),
although the time effect approached statistical signifi-
cance (p = 0.13). Data are presented in Figure 5C.
Discussion
Findings from the present investigation indicate that
Ambrotose AO® supplementation at a dosage of 4 cap-
sules per day given to young, healthy, exercise trained
and untrained men and women increased resting blood
antioxidant capacity and appeared to be well-tolerated
and safe, based on subject reporting in addition to com-
plete blood count, metabolic, and lipid panel data. The
supplement also enhanced the 30 minute post exercise
Table 2 Capsule compliance, quality of life (SF-12) and graded exercise test (GXT) time to exhaustion data of men (A)
and women (B) before and following three weeks of supplementation with Ambrotose AO® at a dosage of 4 capsules
per day and placebo (cross-over design with a three week washout between conditions)
A
Variable Trained Men
Ambrotose
AO® Pre
Trained Men
Ambrotose
AO® Post
Trained
Men
Placebo
Pre
Trained
Men
Placebo
Post
Untrained Men
Ambrotose AO®
Pre
Untrained Men
Ambrotose AO®
Post
Untrained
Men
Placebo Pre
Untrained
Men Placebo
Post
% Capsule
Compliance†
NA 91.9 ± 5.5 NA 98.6 ± 1.1 NA 88.6 ± 5.5 NA 89.8 ± 7.0
Physical
Health†
55.4 ± 2.5 56.7 ± 1.1 57.9 ± 1.2 56.9 ± 0.8 51.2 ± 4.6 48.4 ± 3.5 54.0 ± 1.2 55.0 ± 1.6
Mental
Health**
55.3 ± 1.7 54.7 ± 2.3 55.1 ± 2.7 55.1 ± 1.9 48.5 ± 6.5 52.4 ± 5.3 49.2 ± 3.8 49.4 ± 3.6
Exercise
Time (sec)†*
NA 1252 ± 45 NA 1275 ± 47 NA 956 ± 65 NA 989 ± 88
B
Variable Trained
Women
Ambrotose
AO® Pre
Trained
Women
Ambrotose
AO® Post
Trained
Women
Placebo
Pre
Trained
Women
Placebo
Post
Untrained
Women
Ambrotose AO®
Pre
Untrained
Women
Ambrotose AO®
Post
Untrained
Women
Placebo Pre
Untrained
Women
Placebo Post
% Capsule
Compliance†
NA 96.3 ± 1.3 NA 93.2 ± 2.6 NA 82.5 ± 8.7 NA 89.8 ± 5.5
Physical
Health†
56.6 ± 1.0 55.3 ± 1.8 57.9 ± 1.7 56.3 ± 2.3 54.7 ± 1.3 54.7 ± 2.1 54.2 ± 2.4 53.7 ± 1.6
Mental
Health**
50.3 ± 2.6 49.9 ± 2.5 49.7 ± 3.0 51.6 ± 3.0 54.0 ± 2.2 53.2 ± 3.8 51.4 ± 2.1 53.7 ± 1.5
Exercise
Time (sec)†*
NA 1062 ± 59 NA 1064 ± 66 NA 839 ± 80 NA 853 ± 76
Values are mean ± SEM.
†Training status effect: Capsule Compliance (p = 0.04); Physical Health (p = 0.0008); Exercise Time (p < 0.0001).
*Sex effect: Exercise Time (p = 0.001).
**Sex × training status effect: Mental Health (p = 0.02).
No other statistically significant differences were noted (p > 0.05).
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Page 7 of 17antioxidant capacity of blood, as measured by serum
ORAC. However, no statistically detected difference was
observed in resting or exercise-induced oxidative stress
biomarkers, physical or mental quality of life, or exercise
time to exhaustion. In comparing to recent literature,
some expected differences between men and women
[23,24], as well as between trained and untrained sub-
jects [23], were also observed.
The data presented above from a controlled, double-
blind research study are compatible with the results in
Table 3 Complete blood count data of men (A) and women (B) before and following three weeks of supplementation
with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three week washout
between conditions)
A
Variable Trained Men
Ambrotose
AO® Pre
Trained Men
Ambrotose
AO® Post
Trained
Men
Placebo
Pre
Trained
Men
Placebo
Post
Untrained Men
Ambrotose
AO® Pre
Untrained Men
Ambrotose
AO® Post
Untrained
Men
Placebo Pre
Untrained
Men
Placebo
Post
WBC (10
3 μL)† 4.5 ± 0.1 4.5 ± 0.2 5.1 ± 0.6 4.9 ± 0.3 5.7 ± 0.5 6.0 ± 0.4 5.9 ± 0.5 5.6 ± 0.5
RBC (10
6 μL)* 4.9 ± 0.1 4.7 ± 0.1 4.9 ± 0.1 4.8 ± 0.1 4.7 ± 0.2 4.6 ± 0.2 4.6 ± 0.3 4.6 ± 0.2
Hemoglobin
(g·dL
-1)*
14.7 ± 0.3 13.3 ± 0.5 14.8 ± 0.4 14.6 ± 0.3 14.8 ± 0.5 14.6 ± 0.5 14.6 ± 0.6 14.4 ± 0.4
Hematocrit (%)†* 43.3 ± 0.8 41.8 ± 1.1 43.5 ± 1.0 42.3 ± 0.5 43.0 ± 1.0 41.9 ± 1.2 42.2 ± 2.0 41.2 ± 1.3
MCV (fL)** 88.7 ± 2.2 89.0 ± 2.5 88.3 ± 2.3 88.3 ± 2.2 91.2 ± 2.6 90.8 ± 2.3 91.6 ± 2.2 91.0 ± 2.5
MCH (pg)** 30.2 ± 1.0 30.5 ± 1.0 29.9 ± 1.0 30.3 ± 0.9 31.4 ± 1.0 31.7 ± 1.0 31.7 ± 1.0 31.9 ± 1.1
MCHC (g·dL
-1)** 34.0 ± 0.4 34.2 ± 0.2 33.9 ± 0.4 34.4 ± 0.4 34.5 ± 0.4 34.9 ± 0.3 34.5 ± 0.3 35.0 ± 0.4
RDW (%)** 13.8 ± 0.4 13.2 ± 0.3 13.6 ± 0.3 13.5 ± 0.3 13.0 ± 0.2 13.1 ± 0.2 12.9 ± 0.2 12.9 ± 0.2
Platelets (10
3 μL)* 208.0 ± 16.7 204.0 ± 13.9 214.4 ±
16.1
211.4 ± 21.7 217.6 ± 20.4 203.2 ± 21.0 208.0 ± 24.5 209.6 ± 24.3
Neutrophils (%) 51.1 ± 4.5 50.0 ± 3.4 52.7 ± 4.9 51.0 ± 4.6 54.2 ± 2.6 58.0 ± 4.6 52.8 ± 2.1 53.6 ± 3.6
Lymphocytes (%) 36.0 ± 3.8 37.4 ± 3.2 36.0 ± 4.4 36.4 ± 4.3 32.6 ± 2.1 30.2 ± 4.1 34.2 ± 1.3 33.5 ± 2.9
Monocytes (%)† 7.7 ± 0.6 8.6 ± 0.8 7.6 ± 0.6 8.3 ± 0.5 7.4 ± 0.9 7.2 ± 1.2 7.0 ± 0.5 7.1 ± 0.9
Eosinophils (%)* 4.9 ± 1.8 3.7 ± 0.8 3.1 ± 0.7 3.9 ± 0.6 5.2 ± 1.6 4.0 ± 1.0 5.8 ± 1.8 5.3 ± 1.8
Basophils (%) 0.3 ± 0.2 0.3 ± 0.2 0.6 ± 0.2 0.4 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.2 ± 0.2 0.5 ± 0.2
B
Variable Trained
Women
Ambrotose
AO® Pre
Trained
Women
Ambrotose
AO® Post
Trained
Women
Placebo
Pre
Trained
Women
Placebo
Post
Untrained
Women
Ambrotose
AO® Pre
Untrained
Women
Ambrotose
AO® Post
Untrained
Women
Placebo Pre
Untrained
Women
Placebo
Post
WBC (10
3 μL)† 5.1 ± 1.0 5.2 ± 0.7 4.7 ± 0.4 5.3 ± 0.7 5.6 ± 0.5 4.9 ± 0.3 5.0 ± 0.4 6.0 ± 0.8
RBC (10
6 μL)* 4.2 ± 0.1 4.1 ± 0.1 4.2 ± 0.1 4.2 ± 0.1 4.2 ± 0.1 4.1 ± 0.1 4.2 ± 0.1 4.2 ± 0.2
Hemoglobin
(g·dL
-1)*
13.4 ± 0.4 12.8 ± 0.3 13.2 ± 0.1 13.2 ± 0.2 12.5 ± 0.3 12.1 ± 0.4 12.3 ± 0.5 12.4 ± 0.6
Hematocrit (%)†* 38.8 ± 1.0 37.1 ± 0.9 38.6 ± 0.4 37.9 ± 0.6 36.9 ± 0.8 35.0 ± 0.8 36.6 ± 1.4 36.5 ± 1.5
MCV (fL)** 91.9 ± 1.7 91.4 ± 1.8 91.4 ± 2.0 90.8 ± 2.0 87.1 ± 1.2 85.8 ± 0.7 86.5 ± 0.9 86.2 ± 0.9
MCH (pg)** 31.7 ± 0.7 31.6 ± 0.7 31.1 ± 0.7 31.5 ± 0.7 29.6 ± 0.4 29.7 ± 0.4 29.0 ± 0.4 29.3 ± 0.6
MCHC (g·dL
-1)** 34.6 ± 0.2 34.6 ± 0.2 34.1 ± 0.2 34.7 ± 0.2 33.9 ± 0.2 34.6 ± 0.3 33.6 ± 0.2 33.9 ± 0.4
RDW (%)** 13.1 ± 0.3 13.3 ± 0.3 13.2 ± 0.2 13.5 ± 0.3 13.3 ± 0.5 13.6 ± 0.6 13.7 ± 0.6 13.7 ± 0.6
Platelets (10
3 μL)* 234.3 ± 20.0 229.1 ± 17.1 246.1 ±
23.6
236.1 ± 18.8 256.9 ± 29.9 259.2 ± 25.4 254.8 ± 35.6 267.0 ± 34.2
Neutrophils (%) 54.1 ± 5.5 56.3 ± 4.8 57.7 ± 4.7 58.8 ± 3.9 57.3 ± 3.5 56.0 ± 2.0 53.8 ± 3.2 58.3 ± 3.4
Lymphocytes (%) 34.3 ± 4.9 31.0 ± 4.0 30.6 ± 4.4 29.3 ± 3.2 34.3 ± 3.5 35.8 ± 1.8 36.5 ± 2.6 32.5 ± 3.0
Monocytes (%)† 8.0 ± 0.9 9.0 ± 1.0 7.3 ± 0.4 8.4 ± 0.6 6.1 ± 0.5 6.0 ± 0.5 6.2 ± 0.7 5.5 ± 0.8
Eosinophils (%)* 3.0 ± 0.5 3.3 ± 0.9 3.4 ± 0.6 3.0 ± 0.6 1.7 ± 0.5 1.8 ± 0.2 3.0 ± 0.6 2.7 ± 0.5
Basophils (%) 0.6 ± 0.2 0.4 ± 0.2 1.0 ± 0.0 0.5 ± 0.2 0.6 ± 0.2 0.3 ± 0.2 0.5 ± 0.2 0.5 ± 0.2
Values are mean ± SEM.
†Training status effect: WBC (p = 0.02); Hematocrit (p = 0.02); Monocytes (p = 0.0001).
*Sex effect: RBC (p < 0.0001); Hemoglobin (p < 0.0001); Hematocrit (p < 0.0001); Platelets (p = 0.004); Eosinophils (p = 0.002).
**Sex × training status effect: MVC (p = 0.0002); MCH (p < 0.0001); MCHC (p = 0.008); RDW (p = 0.03).
No other statistically significant differences were noted (p > 0.05).
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Page 8 of 17Table 4 Comprehensive metabolic panel data of men (A) and women (B) before and following three weeks of
supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three
week washout between conditions)
A
Variable Trained Men
Ambrotose
AO® Pre
Trained Men
Ambrotose
AO® Post
Trained
Men
Placebo
Pre
Trained
Men
Placebo
Post
Untrained Men
Ambrotose
AO® Pre
Untrained Men
Ambrotose
AO® Post
Untrained
Men
Placebo Pre
Untrained
Men
Placebo
Post
Glucose (mg·dL
-1)** 84.3 ± 3.8 87.0 ± 4.6 87.4 ± 3.6 83.9 ± 2.3 90.4 ± 3.4 95.8 ± 5.4 99.6 ± 9.0 96.2 ± 9.1
BUN (mg·dL
-1)†* 16.9 ± 1.9 16.7 ± 1.0 16.7 ± 1.6 17.9 ± 1.8 15.0 ± 2.3 15.8 ± 2.5 14.6 ± 1.0 13.4 ± 1.2
Creatinine
(mg·dL
-1)†*
1.1 ± 0.0 1.1 ± 0.0 1.2 ± 0.0 1.1 ± 0.0 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
BUN/Creatinine 15.6 ± 2.0 15.4 ± 1.4 14.6 ± 1.3 16.0 ± 1.7 15.4 ± 3.2 16.2 ± 3.7 13.6 ± 1.9 12.2 ± 1.4
Sodium (mmol·L
-1) 138.4 ± 0.3 139.9 ± 0.6 139.3 ± 0.6 138.3 ± 0.8 137.2 ± 0.4 137.4 ± 0.6 138.8 ± 1.1 137.6 ± 1.3
Potassium
(mmol·L
-1)
4.5 ± 0.2 4.3 ± 0.2 4.3 ± 0.2 4.3 ± 0.2 4.4 ± 0.1 4.2 ± 0.1 4.1 ± 0.1 4.3 ± 0.1
Chloride (mmol·L
-1)* 102.0 ± 0.4 103.1 ± 0.3 101.7 ± 0.9 101.9 ± 0.5 101.6 ± 0.9 101.6 ± 0.8 102.6 ± 1.4 102.2 ± 1.3
CO2 (mmol·L
-1)* 26.7 ± 0.7 26.9 ± 0.6 26.7 ± 0.5 26.4 ± 0.7 26.0 ± 0.7 24.8 ± 0.7 26.2 ± 0.7 25.4 ± 0.5
Calcium (mg·dL
-1)* 9.2 ± 0.2 9.3 ± 0.1 9.4 ± 0.1 9.4 ± 0.1 9.4 ± 0.1 9.2 ± 0.1 9.2 ± 0.1 9.3 ± 0.1
Protein (g·dL
-1)†* 6.7 ± 0.1 6.6 ± 0.1 6.8 ± 0.1 6.8 ± 0.1 7.0 ± 0.2 6.9 ± 0.2 6.8 ± 0.1 6.7 ± 0.2
Albumin (g·dL
-1) 4.3 ± 0.1 4.3 ± 0.1 4.4 ± 0.2 4.3 ± 0.1 4.5 ± 0.1 4.4 ± 0.2 4.3 ± 0.0 4.1 ± 0.1
Globulin (g·dL
-1)†* 2.4 ± 0.2 2.4 ± 0.2 2.5 ± 0.2 2.5 ± 0.1 2.5 ± 0.1 2.5 ± 0.1 2.4 ± 0.1 2.6 ± 0.1
A/G Ratio†* 1.8 ± 0.1 1.9 ± 0.2 1.8 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.6 ± 0.1
Bilirubin (mg·dL
-1)** 0.7 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.5 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.8 ± 0.2 0.9 ± 0.2
Alk Phos (IU·L
-1)* 71.7 ± 6.7 71.6 ± 6.7 75.3 ± 6.7 73.4 ± 6.2 68.2 ± 9.6 68.0 ± 9.0 69.0 ± 8.9 65.6 ± 10.3
AST (SGOT) (IU·L
-1)** 25.6 ± 1.8 24.9 ± 3.4 27.1 ± 2.9 25.0 ± 1.6 25.2 ± 2.9 30.8 ± 3.5 30.6 ± 3.6 30.6 ± 4.3
ALT (SGPT) (IU·L
-1)** 23.7 ± 2.1 26.0 ± 3.0 26.4 ± 3.2 27.1 ± 4.4 25.6 ± 7.0 33.2 ± 11.8 39.4 ± 11.9 33.0 ± 7.7
B
Variable Trained
Women
Ambrotose
AO® Pre
Trained
Women
Ambrotose
AO® Post
Trained
Women
Placebo
Pre
Trained
Women
Placebo
Post
Untrained
Women
Ambrotose
AO® Pre
Untrained
Women
Ambrotose
AO® Post
Untrained
Women
Placebo Pre
Untrained
Women
Placebo
Post
Glucose (mg·dL
-1)** 86.1 ± 3.3 86.7 ± 1.9 88.1 ± 2.5 97.1 ± 10.3 84.6 ± 1.9 84.8 ± 2.5 86.0 ± 1.6 82.8 ± 2.7
BUN (mg·dL
-1)†* 14.9 ± 1.9 15.7 ± 1.9 15.6 ± 2.2 17.1 ± 2.2 11.0 ± 1.3 11.2 ± 1.4 12.5 ± 1.9 12.5 ± 2.1
Creatinine
(mg·dL
-1)†*
1.0 ± 0.0 0.9 ± 0.0 1.0 ± 0.1 0.9 ± 0.1 0.8 ± 0.0 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.0
BUN/Creatinine 15.4 ± 2.1 16.6 ± 2.2 16.7 ± 2.7 19.1 ± 2.9 13.7 ± 1.6 14.5 ± 2.3 15.2 ± 2.5 15.3 ± 2.9
Sodium (mmol·L
-1) 138.9 ± 0.7 138.4 ± 0.8 139.0 ± 0.9 138.0 ± 0.6 139.3 ± 0.8 138.3 ± 0.9 139.0 ± 0.9 138.3 ± 0.6
Potassium
(mmol·L
-1)
4.1 ± 0.1 4.1 ± 0.2 4.2 ± 0.1 4.3 ± 0.1 4.3 ± 0.1 4.1 ± 0.1 4.1 ± 0.1 4.4 ± 0.2
Chloride (mmol·L
-1)* 103.1 ± 0.5 103.4 ± 0.8 103.6 ± 0.8 103.4 ± 1.0 102.6 ± 1.2 103.0 ± 0.9 103.7 ± 0.6 103.0 ± 0.5
CO2 (mmol·L
-1)* 23.7 ± 0.8 24.4 ± 1.2 25.1 ± 1.0 24.4 ± 0.5 24.1 ± 1.1 24.0 ± 0.4 24.0 ± 0.3 24.0 ± 0.4
Calcium (mg·dL
-1)* 9.6 ± 0.2 9.5 ± 0.2 9.5 ± 0.1 9.6 ± 0.1 9.4 ± 0.1 9.3 ± 0.1 9.4 ± 0.1 9.5 ± 0.1
Protein (g·dL
-1)†* 7.0 ± 0.2 6.7 ± 0.2 6.9 ± 0.1 6.7 ± 0.2 7.1 ± 0.2 7.2 ± 0.1 7.4 ± 0.2 7.4 ± 0.2
Albumin (g·dL
-1) 4.5 ± 0.1 4.2 ± 0.1 4.3 ± 0.1 4.2 ± 0.1 4.4 ± 0.1 4.3 ± 0.1 4.5 ± 0.1 4.4 ± 0.1
Globulin (g·dL
-1)†* 2.5 ± 0.1 2.5 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 2.8 ± 0.2 2.9 ± 0.1 2.9 ± 0.2 3.0 ± 0.2
A/G Ratio†* 1.8 ± 0.1 1.7 ± 0.0 1.7 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 1.5 ± 0.1
Bilirubin (mg·dL
-1)** 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.7 ± 0.2 0.4 ± 0.1 0.5 ± 0.0 0.4 ± 0.1 0.4 ± 0.1
Alk Phos (IU·L
-1)* 55.4 ± 6.5 51.9 ± 5.1 56.0 ± 4.5 49.6 ± 4.6 53.1 ± 6.9 53.7 ± 5.2 56.2 ± 6.8 58.3 ± 7.8
AST (SGOT) (IU·L
-1)** 25.4 ± 2.8 29.3 ± 5.8 20.3 ± 2.1 23.3 ± 1.1 19.6 ± 2.5 18.8 ± 1.6 21.3 ± 1.7 23.2 ± 3.2
ALT (SGPT) (IU·L
-1)** 22.1 ± 3.1 24.3 ± 4.7 19.9 ± 2.4 19.1 ± 1.5 16.3 ± 3.6 13.7 ± 2.2 14.0 ± 1.2 18.8 ± 3.8
Values are mean ± SEM.
†Training status effect: BUN (p = 0.002); Creatinine (p < 0.0001); Protein (p = 0.001); Globulin (p = 0.003); A/G Ratio (p = 0.04).
*Sex effect: BUN (p = 0.05); Creatinine (p = 0.002); Chloride (p = 0.008); CO2 (p < 0.0001); Calcium (p = 0.03); Protein (p = 0.002); Globulin (p = 0.006); A/G Ratio
(p = 0.05); Alk Phos (p < 0.0001).
**Sex × training status effect: Glucose (p = 0.005); Bilirubin (p = 0.01); AST (p = 0.02); ALT (p = 0.01).
No other statistically significant differences were noted (p > 0.05).
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Page 9 of 17previous preliminary open-label studies which support
the use of Ambrotose AO® as an antioxidant supplement.
Based on these findings, we accept our hypothesis that
Ambrotose AO® would increase resting antioxidant capa-
city, but reject our hypothesis that we would note a
decrease in oxidative stress biomarkers. Additionally, we
accept our hypothesis that acute exercise would result in
an increase in oxidative stress in both conditions, but
reject our hypothesis that attenuation would be observed
with Ambrotose AO® treatment (with the exception of a
higher ORAC value at 30 minutes post exercise).
The changes noted in blood antioxidant capacity from
pre to post intervention are similar to, albeit slightly less
than, those reported in the previous two open-label
designs using Ambrotose AO® [15,16]. Moreover, our
increases of approximately 22% in ORAC and 19% in
TEAC are similar to other previously published work
using either whole foods or antioxidant supplements. For
example, an increase in serum ORAC has been docu-
mented following ingestion of strawberries (14.4%) and
spinach (28.5%) [25], buckwheat honey (7%) [26], and
concord grape juice (8%) [27]. In contrast, ingestion of a
h i g h - c a r o t e n o i dc o n t e n td i e th a dn oe f f e c to ns e r u m
ORAC [28]. The results of dietary supplementation trials
on serum ORAC have been mixed. For example, in a
placebo-controlled trial of healthy adults, a single 100 g
dose of wild blueberry powder significantly increased
serum ORAC by up to 16% [29] and a single relatively
high (1.25 g) dose of vitamin C increased serum ORAC
by 23% [25]. In a second placebo-controlled study of 500
mg/day vitamin C, serum ORAC was noted to be signifi-
cantly increased, (2.5%) [30].I nc o n t r a s tt ot h e s ef i n d -
ings, other supplementation studies did not show
any effect on serum ORAC: an antioxidant supplement
(vitamin E, beta-carotene, ascorbic acid, selenium, alpha-
lipoic acid, N-acetyl 1-cysteine, catechin, lutein, and lyco-
pene) [31]; either of two antioxidant supplements (an
antioxidant vitamin/mineral tablet or a vitamin/mineral/
fruit and vegetable powder capsule) [28]; or a fruit-based
antioxidant drink [32]. Clearly, data are mixed with
regards to dietary supplements to increase blood antioxi-
dant status. Discrepancies may be related to the health
status of the subject population, the subjects’ starting
antioxidant status, the bioavailability of the supplement,
and the time course of treatment. As with many nutri-
tional supplements, optimal benefits of Ambrotose AO®
may be observed with chronic intake.
While we noted significant increases in blood antioxi-
dant capacity with Ambrotose AO® given at 2000 mg
p e rd a y ,i ti su n k n o w nw h e t h e ro rn o tal o w e rd o s a g e
Table 5 Blood lipid data of men (A) and women (B) before and following three weeks of supplementation with
Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three week washout
between conditions)
A
Variable Trained Men
Ambrotose
AO® Pre
Trained Men
Ambrotose
AO® Post
Trained
Men
Placebo Pre
Trained
Men
Placebo
Post
Untrained
Men
Ambrotose
AO® Pre
Untrained Men
Ambrotose
AO® Post
Untrained
Men
Placebo
Pre
Untrained
Men
Placebo
Post
Cholesterol (mg·dL
-1)† 155.7 ± 9.7 149.0 ± 5.4 160.7 ± 12.1 159.9 ± 9.6 173.0 ± 13.6 169.8 ± 16.4 171.2 ± 13.6 173.6 ± 16.1
Triglycerides (mg·dL
-1)* 82.3 ± 11.6 93.6 ± 16.4 98.7 ± 17.7 95.3 ± 14.5 103.6 ± 31.6 80.2 ± 16.8 69.2 ± 10.6 94.0 ± 32.3
HDL-C (mg·dL
-1)* 44.7 ± 2.9 45.1 ± 3.5 45.2 ± 3.0 47.0 ± 3.6 51.2 ± 6.1 53.0 ± 3.8 51.8 ± 4.0 46.2 ± 5.7
VLDL-C (mg·dL
-1)* 16.6 ± 2.3 18.6 ± 3.2 19.7 ± 3.5 19.1 ± 2.8 20.8 ± 6.4 16.0 ± 3.4 14.0 ± 2.0 18.8 ± 6.5
LDL-C (mg·dL
-1)†* 94.4 ± 8.5 85.3 ± 3.9 95.6 ± 9.8 93.7 ± 8.0 101.0 ± 13.2 100.8 ± 15.4 105.4 ± 13.7 108.6 ± 16.2
LDL/HDL* 2.2 ± 0.3 2.0 ± 0.2 2.2 ± 0.3 2.1 ± 0.3 2.2 ± 0.6 2.0 ± 0.4 2.1 ± 0.5 2.7 ± 0.7
B
Variable Trained
Women
Ambrotose
AO® Pre
Trained
Women
Ambrotose
AO® Post
Trained
Women
Placebo Pre
Trained
Women
Placebo
Post
Untrained
Women
Ambrotose
AO® Pre
Untrained
Women
Ambrotose
AO® Post
Untrained
Women
Placebo
Pre
Untrained
Women
Placebo
Post
Cholesterol (mg·dL
-1)† 153.0 ± 5.8 146.7 ± 12.6 160.0 ± 14.2 154.7 ± 11.4 169.7 ± 9.4 167.7 ± 10.1 174.0 ± 6.4 175.3 ± 7.3
Triglycerides (mg·dL
-1)* 56.0 ± 6.9 52.1 ± 6.1 69.1 ± 11.2 66.3 ± 10.5 66.0 ± 8.6 70.3 ± 20.6 63.0 ± 11.4 71.5 ± 20.8
HDL-C (mg·dL
-1)* 65.1 ± 4.3 63.1 ± 6.7 65.1 ± 7.6 61.7 ± 6.7 60.9 ± 3.5 62.8 ± 5.6 64.3 ± 6.1 69.2 ± 6.3
VLDL-C (mg·dL
-1)* 11.3 ± 1.4 10.4 ± 1.2 14.0 ± 2.3 13.3 ± 2.2 13.1 ± 1.8 14.0 ± 4.1 12.8 ± 2.3 14.2 ± 4.1
LDL-C (mg·dL
-1)†* 76.6 ± 5.5 73.1 ± 6.1 80.9 ± 6.9 79.7 ± 6.4 95.7 ± 9.0 90.8 ± 9.3 96.8 ± 7.9 92.0 ± 8.7
LDL/HDL* 1.2 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.6 ± 0.1 1.5 ± 0.2 1.6 ± 0.2 1.4 ± 0.2
Values are mean ± SEM.
†Training status effect: Cholesterol (p = 0.009); LDL-C (p = 0.009).
*Sex effect: Triglycerides (p = 0.0005); HDL-C (p < 0.0001); VLDL-C (p = 0.0006); LDL-C (p = 0.002); LDL/HDL (p < 0.001).
No other statistically significant differences were noted (p > 0.05).
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Page 10 of 17could provide similar effects, or whether a higher dosage
could provide even more favorable effects. Moreover,
while our data are in reference to a sample of young
and healthy individuals, it is possible that older, decon-
ditioned or diseased individuals might experience more
robust changes in our chosen outcome measures. While
we chose to include more “global” measures of antioxi-
dant capacity, an analysis of individual enzymatic and
non-enzymatic antioxidants before and after treatment
with Ambrotose AO® would be of interest. Lastly, while
we chose to use an exercise stressor in the present
study, it is possible that other stressors such as high fat
or high sugar feedings may better assess the antioxidant
potential of the Ambrotose AO® supplement. Future
research is needed to provide answers to the above
questions.
We noted an increase in resting antioxidant capacity
with Ambrotose AO® supplementation, but no statisti-
cally detected difference was observed in resting or exer-
cise-induced oxidative stress biomarkers between
conditions. In relation to the resting data, it is possible
that our lack of finding for a decrease in resting oxida-
tive stress biomarkers with Ambrotose AO® treatment is
related to the relatively low initial values displayed by
our subjects, similar to values we have recently reported
for well-trained men and women [23]. Despite any
potential antioxidant effect of the Ambrotose AO®, there
may be little need to further decrease the already low
resting levels of these oxidative stress biomarkers. This
is especially true in light of the fact that a mild degree
of oxidative stress, and RONS production promoting
such a condition, appears a vital component of normal,
healthy physiological functioning [33]. Perhaps the
inclusion of individuals with higher resting oxidative
stress values would allow for changes of statistical signif-
icance in relation to our chosen biomarkers.
In relation to the exercise-induced findings, our data
agree with many previous reports demonstrating a small
and transient increase in antioxidant capacity and oxida-
tive stress biomarkers in response to acute aerobic exer-
cise. We have recently presented the most comprehensive
review to date on this topic, with the inclusion of over 300
original investigations [3]. In this review it is evident that
acute exercise, whether aerobic or anaerobic has the
potential to increase oxidative stress as measured in
human blood samples. While this is certainly not a univer-
sal finding, most studies indicate at least a mild oxidative
stress in response to acute, strenuous exercise (often of
long duration) in both men and women, and in both exer-
cise-trained and untrained individuals. Our data support
these findings, evidenced by a transient increase in
all measured variables (with the exception of NOx) at
Table 6 Dietary data of men (A) and women (B) during the seven days before exercise testing following three weeks
of supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a
three week washout between conditions)
A
Variable Trained Men Ambrotose AO® Trained Men Placebo Untrained Men Ambrotose AO® Untrained Men Placebo
Kilocalories** 2463 ± 68 2764 ± 202 1958 ± 373 1880 ± 331
Protein (g)†* 107 ± 9 123 ± 8 88 ± 20 98 ± 29
Carbohydrate (g)** 329 ± 22 362 ± 35 234 ± 58 197 ± 55
Fat (g)* 85 ± 8 94 ± 11 64 ± 12 68 ± 9
Vitamin C (mg)†* 253 ± 108 193 ± 48 83 ± 38 90 ± 31
Vitamin E (mg) 7 ± 2 8 ± 1 16 ± 13 9 ± 4
Vitamin A (RE)* 10499 ± 3377 7488 ± 1847 4894 ± 1068 8030 ± 2768
B
Variable Trained Women Ambrotose
AO®
Trained Women
Placebo
Untrained Women Ambrotose
AO®
Untrained Women
Placebo
Kilocalories** 1589 ± 99 1368 ± 143 1289 ± 153 1478 ± 179
Protein (g)†* 89 ± 16 79 ± 17 54 ± 9 66 ± 9
Carbohydrate (g)** 177 ± 21 156 ± 19 160 ± 16 176 ± 13
Fat (g)* 55 ± 5 44 ± 4 48 ± 10 58 ± 13
Vitamin C (mg)†* 89 ± 31 58 ± 13 39 ± 11 64 ± 14
Vitamin E (mg) 6 ± 2 6 ± 2 3 ± 1 4 ± 2
Vitamin A (RE)* 4118 ± 926 5494 ± 1685 2561 ± 652 2440 ± 537
Values are mean ± SEM.
†Training status effect: Protein (p = 0.05); Vitamin C (p = 0.03).
*Sex effect: Protein (p = 0.007); Fat (p = 0.0006); Vitamin C (p = 0.01); Vitamin A (p = 0.006).
**Sex × training status effect: Kilocalories (p = 0.04); Carbohydrate (p < 0.002);
No other statistically significant differences were noted (p > 0.05).
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Page 11 of 170 minutes post exercise, with a rapid return towards base-
line values at 30 minutes post exercise–while serum
ORAC was elevated above pre exercise at this time.
With regards to the use of antioxidant supplementation
in an attempt to attenuate the exercise-induced increase
in oxidative stress biomarkers, several investigations have
been conducted over the past two decades. The only
statement that can be made with confidence at the pre-
sent time is that the results are largely mixed [3,34], and
are likely dependent on the type, dosage, and time frame
of treatment of the antioxidant(s), the tissue sampled
(e.g., skeletal muscle, blood), the exercise protocol used to
induce oxidative stress, the time frame of measurement,
the assays used to measure the degree of oxidative stress,
the test subjects recruited (i.e., trained vs. untrained, old
vs. young, healthy vs. diseased, well-nourished vs. mal-
nourished), among other variables [19]. Detailed reviews
of this topic have been presented elsewhere [35,36].
Due to these factors, and considering the individual
response to antioxidant treatment, it is not surprising
Figure 2 Serum Trolox Equivalent Antioxidant Capacity (TEAC) and Oxygen Radical Absorbance Capacity (ORAC) of 25 subjects (12
men and 13 women) before and following three weeks of supplementation with Ambrotose AO® at a dosage of 4 capsules per day
and placebo (cross-over design with a three week washout between conditions). Values are mean ± SEM. For TEAC: Condition × time
interaction (p = 0.17). *Paired contrast between pre and post intervention for Ambrotose AO® (p = 0.02). For ORAC: Condition × time interaction
(p = 0.01). *Paired contrast between pre and post intervention for Ambrotose AO® (p < 0.0001).
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Page 12 of 17Figure 3 Plasma Malondialdehyde (MDA), Hydrogen Peroxide (H2O2), and Nitrate/Nitrite (NOx) of 25 subjects (12 men and 13 women)
before and following three weeks of supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-
over design with a three week washout between conditions). Values are mean ± SEM. For MDA: Condition × time interaction (p = 0.77).
Paired contrast between pre and post intervention for Ambrotose AO® (p = 0.61). For H2O2: Condition × time interaction (p = 0.53). Paired
contrast between pre and post intervention for Ambrotose AO® (p = 0.41). For NOx: Condition × time interaction (p = 0.11). Paired contrast
between pre and post intervention for Ambrotose AO® (p = 0.12).
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Page 13 of 17that we failed to note a statistically significant reduction
in exercise-induced oxidative stress in the present study
(although that was contrary to our initial directional
hypothesis). The reality is that while certain subjects will
benefit from pretreatment with antioxidant supplements
for purposes of decreasing exercise-induced oxidative
stress, others may not. The important point to keep in
mind is that the oxidative stress response observed with
moderate duration acute exercise is mild and transient.
S u c har e s p o n s ei sn o tt h o u g h tt ob ed e t r i m e n t a l .T o
the contrary, a low grade oxidative stress appears neces-
sary for various physiological adaptations [37]. Such a
repeated exposure of the system to increased RONS
production from chronic exercise training leads to an
upregulation in the body’s antioxidant defense system
[38], thus providing adaptive protection from RONS
during subsequent exercise sessions, as well as when
exposed to non-exercise related conditions. In fact,
Figure 4 Serum Trolox Equivalent Antioxidant Capacity (TEAC) and Oxygen Radical Absorbance Capacity (ORAC) of 25 subjects (12
men and 13 women) before and at 0 and 30 minutes after a graded exercise treadmill test to exhaustion, before and following three
weeks of supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three week
washout between conditions). Values are mean ± SEM. For TEAC: *Time effect (p = 0.02). For ORAC: Condition × time interaction (p < 0.0001).
*Paired contrast between Ambrotose AO® and placebo (p < 0.0001)
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Page 14 of 17Figure 5 Plasma Malondialdehyde (MDA), Hydrogen Peroxide (H2O2), and Nitrate/Nitrite (NOx) of 25 subjects (12 men and 13 women)
before and at 0 and 30 minutes after a graded exercise treadmill test to exhaustion, before and following three weeks of
supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three week washout
between conditions). Values are mean ± SEM. For MDA: *Time effect (p = 0.05). For H2O2: *Time effect (p < 0.0001).
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Page 15 of 17exercise-induced oxidative stress may operate in a simi-
lar fashion to all other principles of exercise science.
That is, in order for an adaptation to occur (e.g.,
increased antioxidant defense, hypertrophy, strength,
etc.), the physiological stimulus applied (in this case
RONS production) must exceed a certain minimal
threshold, effectively overloading the system.
This above phenomenon is specific to the principle of
hormesis, which states that in response to repeated
exposure to various toxins and/or stressors, the body
undergoes favorable adaptations that result in enhanced
physiological performance and improved physical health
[6,7]. Exercise-induced RONS production leads to the
activation of the redox sensitive transcription factor
nuclear factor (NF)-kappa ()B, which upon activation
leads to the expression of certain antioxidant enzymes
[37]. Therefore, it has been suggested recently, based on
data pertaining to vitamin C supplementation in con-
junction with a period of exercise training, that an
attempt to minimize the post exercise increase in RONS
production (via antioxidant supplementation) may actu-
ally blunt the adaptive increase in antioxidant defenses,
thereby increasing an individual’s susceptibility to pro-
oxidant attack both at rest, as well as following subse-
quent exercise bouts [12,13]. This indeed merits further
investigation.
Aside from blood markers of antioxidant capacity and
oxidative stress, we measured quality of life using a vali-
dated questionnaire (SF-12). No significant differences
were noted between Ambrotose AO® and placebo condi-
tions. Because our subjects were relatively young and
healthy, all reported values for both mental and physical
health that were at the top of the scoring scale prior to
beginning the study. Therefore, they had little room for
improvement when using the Ambrotose AO®, which
helps to explain our lack of effect.
We also measured exercise time to exhaustion for the
GXT and noted no significant difference between
Ambrotose AO® and placebo conditions. This lack of a
physical performance effect of antioxidant supplementa-
tion agrees with previous work, which has noted little to
no improvement in exercise performance following
intake of antioxidants [35,39].
Finally, as a measure of safety and potential interest in
relation to cardiovascular and metabolic parameters
(e.g., blood lipids and glucose), we measured complete
blood count, metabolic panel, and lipid panel values. No
significant differences were noted between Ambrotose
AO® and placebo conditions for any measured variable.
These finding provide safety data in relation to the
short-term (3 week) intake of Ambrotose AO® by young,
healthy subjects.
Considering the results presented within, Ambrotose
AO® may prove to be an effective dietary antioxidant for
purposes of improving resting blood antioxidant capa-
city. While our sample consisted of relatively young and
healthy men and women, it is possible that more robust
effects may be noted within a sample of older indivi-
duals, those with known disease, or within those with
lower antioxidant capacity and higher oxidative stress
due to lifestyle factors (e.g., cigarette smokers). More-
over, while we used an exercise stressor in the present
study in an attempt to increase RONS and to test the
antioxidant potential of Ambrotose AO®, other stressors
such as the ingestion of excess saturated fat or high gly-
cemic carbohydrate feedings may better assess the anti-
oxidant potential of the Ambrotose AO® supplement.
Future research is needed to provide answers to the
above questions.
Conclusion
The findings presented here indicate that Ambrotose
AO® may improve resting blood antioxidant capacity
and may enhance post exercise blood antioxidant capa-
city in young, exercise trained and untrained men and
women. However, this supplement does not appear
necessary for purposes of decreasing exercise-induced
oxidative stress within a sample of young, healthy men
and women.
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